APO Research
Talk to an analyst

APO RESEARCH · REPORT

Thrombogenic Agents

Compare research editions
View pricing & licenses

Selected research

Industry Research

Thrombogenic Agents Industry Research Report 2026

23 December 2025142 pages

Choose your research edition.

Industry ResearchThrombogenic Agents Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Thrombogenic Agents Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Thrombogenic Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Thrombogenic Agents Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Thrombogenic Agents Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Thrombogenic Agents market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Thrombogenic Agents is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Thrombogenic Agents is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Thrombogenic Agents is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Thrombogenic Agents include Chongqing Dikang Yangtze River Pharmaceutical, Zhongbao Pharmaceutical, Wuzhong Medicine Suzhou Pharmaceutical, Tiancheng Pharmaceutical Group, Shanghai RAAS Blood Products, Shandong Taibang Biotechnology, Sanofi, Nuokang Pharmaceutical Group and Novo Nordisk, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Thrombogenic Agents market in terms of revenue (US$ million) and, where applicable, sales volume (units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Thrombogenic Agents Market by Company

Chongqing Dikang Yangtze River Pharmaceutical

Zhongbao Pharmaceutical

Wuzhong Medicine Suzhou Pharmaceutical

Tiancheng Pharmaceutical Group

Shanghai RAAS Blood Products

Shandong Taibang Biotechnology

Sanofi

Nuokang Pharmaceutical Group

Novo Nordisk

Merck

Roche

Chongqing Laimei Pharmaceutical

Jiangsu Yabang Aipson Pharmaceutical

Pfizer

Boya Biopharmaceutical

Amgen

AbbVie

Johnson And Johnson

BristolMyers Squibb

Boehringer Ingelheim

Thrombogenic Agents Segment by Type

Vitamin K Antagonists

Direct Thrombin Inhibitors

Antithrombin Ⅲ Dependent Anticoagulants

Factor Xa Inhibitors

Others

Thrombogenic Agents Segment by Application

Tumor Treatment

Stop Bleeding

Cardiovascular Disease Treatment

Research And Drug Development

Others

Thrombogenic Agents Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Thrombogenic Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Thrombogenic Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Thrombogenic Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Thrombogenic Agents manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Thrombogenic Agents by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Thrombogenic Agents in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Thrombogenic Agents Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Thrombogenic Agents Sales (units) of Manufacturers (2021-2026) Table 7. Global Thrombogenic Agents Sales Market Share by Manufacturers (2021-2026) Table 8. Global Thrombogenic Agents Revenue of Manufacturers (2021-2026) Table 9. Global Thrombogenic Agents Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Thrombogenic Agents Average Price (USD/unit) of Manufacturers (2021-2026) Table 11. Global Thrombogenic Agents Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Thrombogenic Agents, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Thrombogenic Agents, Product Type & Application Table 14. Global Thrombogenic Agents Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Thrombogenic Agents by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Chongqing Dikang Yangtze River Pharmaceutical Company Information Table 19. Chongqing Dikang Yangtze River Pharmaceutical Business Overview Table 20. Chongqing Dikang Yangtze River Pharmaceutical Thrombogenic Agents Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 21. Chongqing Dikang Yangtze River Pharmaceutical Thrombogenic Agents Product Portfolio Table 22. Chongqing Dikang Yangtze River Pharmaceutical Recent Developments Table 23. Zhongbao Pharmaceutical Company Information Table 24. Zhongbao Pharmaceutical Business Overview Table 25. Zhongbao Pharmaceutical Thrombogenic Agents Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 26. Zhongbao Pharmaceutical Thrombogenic Agents Product Portfolio Table 27. Zhongbao Pharmaceutical Recent Developments Table 28. Wuzhong Medicine Suzhou Pharmaceutical Company Information Table 29. Wuzhong Medicine Suzhou Pharmaceutical Business Overview Table 30. Wuzhong Medicine Suzhou Pharmaceutical Thrombogenic Agents Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 31. Wuzhong Medicine Suzhou Pharmaceutical Thrombogenic Agents Product Portfolio Table 32. Wuzhong Medicine Suzhou Pharmaceutical Recent Developments Table 33. Tiancheng Pharmaceutical Group Company Information Table 34. Tiancheng Pharmaceutical Group Business Overview Table 35. Tiancheng Pharmaceutical Group Thrombogenic Agents Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 36. Tiancheng Pharmaceutical Group Thrombogenic Agents Product Portfolio Table 37. Tiancheng Pharmaceutical Group Recent Developments Table 38. Shanghai RAAS Blood Products Company Information Table 39. Shanghai RAAS Blood Products Business Overview Table 40. Shanghai RAAS Blood Products Thrombogenic Agents Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 41. Shanghai RAAS Blood Products Thrombogenic Agents Product Portfolio Table 42. Shanghai RAAS Blood Products Recent Developments Table 43. Shandong Taibang Biotechnology Company Information Table 44. Shandong Taibang Biotechnology Business Overview Table 45. Shandong Taibang Biotechnology Thrombogenic Agents Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 46. Shandong Taibang Biotechnology Thrombogenic Agents Product Portfolio Table 47. Shandong Taibang Biotechnology Recent Developments Table 48. Sanofi Company Information Table 49. Sanofi Business Overview Table 50. Sanofi Thrombogenic Agents Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 51. Sanofi Thrombogenic Agents Product Portfolio Table 52. Sanofi Recent Developments Table 53. Nuokang Pharmaceutical Group Company Information Table 54. Nuokang Pharmaceutical Group Business Overview Table 55. Nuokang Pharmaceutical Group Thrombogenic Agents Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 56. Nuokang Pharmaceutical Group Thrombogenic Agents Product Portfolio Table 57. Nuokang Pharmaceutical Group Recent Developments Table 58. Novo Nordisk Company Information Table 59. Novo Nordisk Business Overview Table 60. Novo Nordisk Thrombogenic Agents Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 61. Novo Nordisk Thrombogenic Agents Product Portfolio Table 62. Novo Nordisk Recent Developments Table 63. Merck Company Information Table 64. Merck Business Overview Table 65. Merck Thrombogenic Agents Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 66. Merck Thrombogenic Agents Product Portfolio Table 67. Merck Recent Developments Table 68. Roche Company Information Table 69. Roche Business Overview Table 70. Roche Thrombogenic Agents Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 71. Roche Thrombogenic Agents Product Portfolio Table 72. Roche Recent Developments Table 73. Chongqing Laimei Pharmaceutical Company Information Table 74. Chongqing Laimei Pharmaceutical Business Overview Table 75. Chongqing Laimei Pharmaceutical Thrombogenic Agents Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. Chongqing Laimei Pharmaceutical Thrombogenic Agents Product Portfolio Table 77. Chongqing Laimei Pharmaceutical Recent Developments Table 78. Jiangsu Yabang Aipson Pharmaceutical Company Information Table 79. Jiangsu Yabang Aipson Pharmaceutical Business Overview Table 80. Jiangsu Yabang Aipson Pharmaceutical Thrombogenic Agents Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. Jiangsu Yabang Aipson Pharmaceutical Thrombogenic Agents Product Portfolio Table 82. Jiangsu Yabang Aipson Pharmaceutical Recent Developments Table 83. Pfizer Company Information Table 84. Pfizer Business Overview Table 85. Pfizer Thrombogenic Agents Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 86. Pfizer Thrombogenic Agents Product Portfolio Table 87. Pfizer Recent Developments Table 88. Boya Biopharmaceutical Company Information Table 89. Boya Biopharmaceutical Business Overview Table 90. Boya Biopharmaceutical Thrombogenic Agents Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Boya Biopharmaceutical Thrombogenic Agents Product Portfolio Table 92. Boya Biopharmaceutical Recent Developments Table 93. Amgen Company Information Table 94. Amgen Business Overview Table 95. Amgen Thrombogenic Agents Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Amgen Thrombogenic Agents Product Portfolio Table 97. Amgen Recent Developments Table 98. AbbVie Company Information Table 99. AbbVie Business Overview Table 100. AbbVie Thrombogenic Agents Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. AbbVie Thrombogenic Agents Product Portfolio Table 102. AbbVie Recent Developments Table 103. Johnson And Johnson Company Information Table 104. Johnson And Johnson Business Overview Table 105. Johnson And Johnson Thrombogenic Agents Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Johnson And Johnson Thrombogenic Agents Product Portfolio Table 107. Johnson And Johnson Recent Developments Table 108. BristolMyers Squibb Company Information Table 109. BristolMyers Squibb Business Overview Table 110. BristolMyers Squibb Thrombogenic Agents Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. BristolMyers Squibb Thrombogenic Agents Product Portfolio Table 112. BristolMyers Squibb Recent Developments Table 113. Boehringer Ingelheim Company Information Table 114. Boehringer Ingelheim Business Overview Table 115. Boehringer Ingelheim Thrombogenic Agents Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Boehringer Ingelheim Thrombogenic Agents Product Portfolio Table 117. Boehringer Ingelheim Recent Developments Table 118. Global Thrombogenic Agents Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 119. Global Thrombogenic Agents Sales by Region (2021-2026) & (units) Table 120. Global Thrombogenic Agents Sales Market Share by Region (2021-2026) Table 121. Global Thrombogenic Agents Sales by Region (2027-2032) & (units) Table 122. Global Thrombogenic Agents Sales Market Share by Region (2027-2032) Table 123. Global Thrombogenic Agents Revenue by Region (2021-2026) & (US$ Million) Table 124. Global Thrombogenic Agents Revenue Market Share by Region (2021-2026) Table 125. Global Thrombogenic Agents Revenue by Region (2027-2032) & (US$ Million) Table 126. Global Thrombogenic Agents Revenue Market Share by Region (2027-2032) Table 127. North America Thrombogenic Agents Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. North America Thrombogenic Agents Sales by Country (2021-2026) & (units) Table 129. North America Thrombogenic Agents Sales by Country (2027-2032) & (units) Table 130. North America Thrombogenic Agents Revenue by Country (2021-2026) & (US$ Million) Table 131. North America Thrombogenic Agents Revenue by Country (2027-2032) & (US$ Million) Table 132. Europe Thrombogenic Agents Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Europe Thrombogenic Agents Sales by Country (2021-2026) & (units) Table 134. Europe Thrombogenic Agents Sales by Country (2027-2032) & (units) Table 135. Europe Thrombogenic Agents Revenue by Country (2021-2026) & (US$ Million) Table 136. Europe Thrombogenic Agents Revenue by Country (2027-2032) & (US$ Million) Table 137. Asia Pacific Thrombogenic Agents Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Asia Pacific Thrombogenic Agents Sales by Country (2021-2026) & (units) Table 139. Asia Pacific Thrombogenic Agents Sales by Country (2027-2032) & (units) Table 140. Asia Pacific Thrombogenic Agents Revenue by Country (2021-2026) & (US$ Million) Table 141. Asia Pacific Thrombogenic Agents Revenue by Country (2027-2032) & (US$ Million) Table 142. South America Thrombogenic Agents Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. South America Thrombogenic Agents Sales by Country (2021-2026) & (units) Table 144. South America Thrombogenic Agents Sales by Country (2027-2032) & (units) Table 145. South America Thrombogenic Agents Revenue by Country (2021-2026) & (US$ Million) Table 146. South America Thrombogenic Agents Revenue by Country (2027-2032) & (US$ Million) Table 147. Middle East and Africa Thrombogenic Agents Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. Middle East and Africa Thrombogenic Agents Sales by Country (2021-2026) & (units) Table 149. Middle East and Africa Thrombogenic Agents Sales by Country (2027-2032) & (units) Table 150. Middle East and Africa Thrombogenic Agents Revenue by Country (2021-2026) & (US$ Million) Table 151. Middle East and Africa Thrombogenic Agents Revenue by Country (2027-2032) & (US$ Million) Table 152. Global Thrombogenic Agents Sales by Type (2021-2026) & (units) Table 153. Global Thrombogenic Agents Sales by Type (2027-2032) & (units) Table 154. Global Thrombogenic Agents Sales Market Share by Type (2021-2026) Table 155. Global Thrombogenic Agents Sales Market Share by Type (2027-2032) Table 156. Global Thrombogenic Agents Revenue by Type (2021-2026) & (US$ Million) Table 157. Global Thrombogenic Agents Revenue by Type (2027-2032) & (US$ Million) Table 158. Global Thrombogenic Agents Revenue Market Share by Type (2021-2026) Table 159. Global Thrombogenic Agents Revenue Market Share by Type (2027-2032) Table 160. Global Thrombogenic Agents Price by Type (2021-2026) & (USD/unit) Table 161. Global Thrombogenic Agents Price by Type (2027-2032) & (USD/unit) Table 162. Global Thrombogenic Agents Sales by Application (2021-2026) & (units) Table 163. Global Thrombogenic Agents Sales by Application (2027-2032) & (units) Table 164. Global Thrombogenic Agents Sales Market Share by Application (2021-2026) Table 165. Global Thrombogenic Agents Sales Market Share by Application (2027-2032) Table 166. Global Thrombogenic Agents Revenue by Application (2021-2026) & (US$ Million) Table 167. Global Thrombogenic Agents Revenue by Application (2027-2032) & (US$ Million) Table 168. Global Thrombogenic Agents Revenue Market Share by Application (2021-2026) Table 169. Global Thrombogenic Agents Revenue Market Share by Application (2027-2032) Table 170. Global Thrombogenic Agents Price by Application (2021-2026) & (USD/unit) Table 171. Global Thrombogenic Agents Price by Application (2027-2032) & (USD/unit) Table 172. Key Raw Materials Table 173. Raw Materials Key Suppliers Table 174. Thrombogenic Agents Distributors List Table 175. Thrombogenic Agents Customers List Table 176. Thrombogenic Agents Industry Trends Table 177. Thrombogenic Agents Industry Drivers Table 178. Thrombogenic Agents Industry Restraints Table 179. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Thrombogenic Agents Product Image Figure 5. Global Thrombogenic Agents Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Thrombogenic Agents Market Size (2021-2032) & (US$ Million) Figure 7. Global Thrombogenic Agents Sales (2021-2032) & (units) Figure 8. Global Thrombogenic Agents Average Price (USD/unit) & (2021-2032) Figure 9. Vitamin K Antagonists Product Image Figure 10. Direct Thrombin Inhibitors Product Image Figure 11. Antithrombin Ⅲ Dependent Anticoagulants Product Image Figure 12. Factor Xa Inhibitors Product Image Figure 13. Others Product Image Figure 14. Tumor Treatment Product Image Figure 15. Stop Bleeding Product Image Figure 16. Cardiovascular Disease Treatment Product Image Figure 17. Research And Drug Development Product Image Figure 18. Others Product Image Figure 19. Global Thrombogenic Agents Revenue Share by Manufacturers in 2025 Figure 20. Global Manufacturers of Thrombogenic Agents, Manufacturing Sites & Headquarters Figure 21. Global Top 5 and 10 Thrombogenic Agents Players Market Share by Revenue in 2025 Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Thrombogenic Agents Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 24. Global Thrombogenic Agents Sales by Region in 2025 Figure 25. Global Thrombogenic Agents Revenue by Region in 2025 Figure 26. North America Thrombogenic Agents Market Size by Country in 2025 Figure 27. North America Thrombogenic Agents Sales Market Share by Country (2021-2032) Figure 28. North America Thrombogenic Agents Revenue Market Share by Country (2021-2032) Figure 29. United States Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Canada Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Mexico Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Europe Thrombogenic Agents Market Size by Country in 2025 Figure 33. Europe Thrombogenic Agents Sales Market Share by Country (2021-2032) Figure 34. Europe Thrombogenic Agents Revenue Market Share by Country (2021-2032) Figure 35. Germany Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. France Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. U.K. Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Italy Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Russia Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Spain Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Netherlands Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Switzerland Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Sweden Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Poland Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Asia Pacific Thrombogenic Agents Market Size by Country in 2025 Figure 46. Asia Pacific Thrombogenic Agents Sales Market Share by Country (2021-2032) Figure 47. Asia Pacific Thrombogenic Agents Revenue Market Share by Country (2021-2032) Figure 48. China Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Japan Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South Korea Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. India Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Australia Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Taiwan Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Southeast Asia Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. South America Thrombogenic Agents Market Size by Country in 2025 Figure 57. South America Thrombogenic Agents Sales Market Share by Country (2021-2032) Figure 58. South America Thrombogenic Agents Revenue Market Share by Country (2021-2032) Figure 59. Brazil Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Argentina Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Chile Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Middle East and Africa Thrombogenic Agents Market Size by Country in 2025 Figure 63. Middle East and Africa Thrombogenic Agents Sales Market Share by Country (2021-2032) Figure 64. Middle East and Africa Thrombogenic Agents Revenue Market Share by Country (2021-2032) Figure 65. Egypt Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. South Africa Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Israel Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Türkiye Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. GCC Countries Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. Global Thrombogenic Agents Sales Market Share by Type (2021-2032) Figure 71. Global Thrombogenic Agents Revenue Market Share by Type (2021-2032) Figure 72. Global Thrombogenic Agents Price (USD/unit) by Type (2021-2032) Figure 73. Global Thrombogenic Agents Sales Market Share by Application (2021-2032) Figure 74. Global Thrombogenic Agents Revenue Market Share by Application (2021-2032) Figure 75. Global Thrombogenic Agents Price (USD/unit) by Application (2021-2032) Figure 76. Thrombogenic Agents Value Chain Figure 77. Thrombogenic Agents Production Mode & Process Figure 78. Direct Comparison with Distribution Share Figure 79. Distributors Profiles Figure 80. Thrombogenic Agents Industry Opportunities and Challenges

Scope & coverage.

Types
  • Vitamin K Antagonists
  • Direct Thrombin Inhibitors
  • Antithrombin Ⅲ Dependent Anticoagulants
  • Factor Xa Inhibitors
  • Others
Applications
  • Tumor Treatment
  • Stop Bleeding
  • Cardiovascular Disease Treatment
  • Research And Drug Development
  • Others
Companies covered
  • Chongqing Dikang Yangtze River Pharmaceutical
  • Zhongbao Pharmaceutical
  • Wuzhong Medicine Suzhou Pharmaceutical
  • Tiancheng Pharmaceutical Group
  • Shanghai RAAS Blood Products
  • Shandong Taibang Biotechnology
  • Sanofi
  • Nuokang Pharmaceutical Group
  • Novo Nordisk
  • Merck
  • Roche
  • Chongqing Laimei Pharmaceutical
  • Jiangsu Yabang Aipson Pharmaceutical
  • Pfizer
  • Boya Biopharmaceutical
  • Amgen
  • AbbVie
  • Johnson And Johnson
  • BristolMyers Squibb
  • Boehringer Ingelheim

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Thrombogenic Agents Market Size (2021-2032)
  4. 2.2.2 Global Thrombogenic Agents Sales (2021-2032)
  5. 2.2.3 Global Thrombogenic Agents Market Average Price (2021-2032)
  6. 2.3 Thrombogenic Agents by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Vitamin K Antagonists
  9. 2.3.3 Direct Thrombin Inhibitors
  10. 2.3.4 Antithrombin Ⅲ Dependent Anticoagulants
  11. 2.3.5 Factor Xa Inhibitors
  12. 2.3.6 Others
  13. 2.4 Thrombogenic Agents by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Tumor Treatment
  16. 2.4.3 Stop Bleeding
  17. 2.4.4 Cardiovascular Disease Treatment
  18. 2.4.5 Research And Drug Development
  19. 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Thrombogenic Agents Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Thrombogenic Agents Sales (units) of Manufacturers (2021-2026)
  3. 3.3 Global Thrombogenic Agents Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Thrombogenic Agents Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Thrombogenic Agents Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Thrombogenic Agents, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Thrombogenic Agents, Product Type & Application
  8. 3.8 Global Manufacturers of Thrombogenic Agents, Established Date
  9. 3.9 Global Thrombogenic Agents Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Chongqing Dikang Yangtze River Pharmaceutical
  2. 4.1.1 Chongqing Dikang Yangtze River Pharmaceutical Company Information
  3. 4.1.2 Chongqing Dikang Yangtze River Pharmaceutical Business Overview
  4. 4.1.3 Chongqing Dikang Yangtze River Pharmaceutical Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Chongqing Dikang Yangtze River Pharmaceutical Thrombogenic Agents Product Portfolio
  6. 4.1.5 Chongqing Dikang Yangtze River Pharmaceutical Recent Developments
  7. 4.2 Zhongbao Pharmaceutical
  8. 4.2.1 Zhongbao Pharmaceutical Company Information
  9. 4.2.2 Zhongbao Pharmaceutical Business Overview
  10. 4.2.3 Zhongbao Pharmaceutical Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Zhongbao Pharmaceutical Thrombogenic Agents Product Portfolio
  12. 4.2.5 Zhongbao Pharmaceutical Recent Developments
  13. 4.3 Wuzhong Medicine Suzhou Pharmaceutical
  14. 4.3.1 Wuzhong Medicine Suzhou Pharmaceutical Company Information
  15. 4.3.2 Wuzhong Medicine Suzhou Pharmaceutical Business Overview
  16. 4.3.3 Wuzhong Medicine Suzhou Pharmaceutical Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Wuzhong Medicine Suzhou Pharmaceutical Thrombogenic Agents Product Portfolio
  18. 4.3.5 Wuzhong Medicine Suzhou Pharmaceutical Recent Developments
  19. 4.4 Tiancheng Pharmaceutical Group
  20. 4.4.1 Tiancheng Pharmaceutical Group Company Information
  21. 4.4.2 Tiancheng Pharmaceutical Group Business Overview
  22. 4.4.3 Tiancheng Pharmaceutical Group Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Tiancheng Pharmaceutical Group Thrombogenic Agents Product Portfolio
  24. 4.4.5 Tiancheng Pharmaceutical Group Recent Developments
  25. 4.5 Shanghai RAAS Blood Products
  26. 4.5.1 Shanghai RAAS Blood Products Company Information
  27. 4.5.2 Shanghai RAAS Blood Products Business Overview
  28. 4.5.3 Shanghai RAAS Blood Products Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Shanghai RAAS Blood Products Thrombogenic Agents Product Portfolio
  30. 4.5.5 Shanghai RAAS Blood Products Recent Developments
  31. 4.6 Shandong Taibang Biotechnology
  32. 4.6.1 Shandong Taibang Biotechnology Company Information
  33. 4.6.2 Shandong Taibang Biotechnology Business Overview
  34. 4.6.3 Shandong Taibang Biotechnology Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Shandong Taibang Biotechnology Thrombogenic Agents Product Portfolio
  36. 4.6.5 Shandong Taibang Biotechnology Recent Developments
  37. 4.7 Sanofi
  38. 4.7.1 Sanofi Company Information
  39. 4.7.2 Sanofi Business Overview
  40. 4.7.3 Sanofi Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Sanofi Thrombogenic Agents Product Portfolio
  42. 4.7.5 Sanofi Recent Developments
  43. 4.8 Nuokang Pharmaceutical Group
  44. 4.8.1 Nuokang Pharmaceutical Group Company Information
  45. 4.8.2 Nuokang Pharmaceutical Group Business Overview
  46. 4.8.3 Nuokang Pharmaceutical Group Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Nuokang Pharmaceutical Group Thrombogenic Agents Product Portfolio
  48. 4.8.5 Nuokang Pharmaceutical Group Recent Developments
  49. 4.9 Novo Nordisk
  50. 4.9.1 Novo Nordisk Company Information
  51. 4.9.2 Novo Nordisk Business Overview
  52. 4.9.3 Novo Nordisk Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Novo Nordisk Thrombogenic Agents Product Portfolio
  54. 4.9.5 Novo Nordisk Recent Developments
  55. 4.10 Merck
  56. 4.10.1 Merck Company Information
  57. 4.10.2 Merck Business Overview
  58. 4.10.3 Merck Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Merck Thrombogenic Agents Product Portfolio
  60. 4.10.5 Merck Recent Developments
  61. 4.11 Roche
  62. 4.11.1 Roche Company Information
  63. 4.11.2 Roche Business Overview
  64. 4.11.3 Roche Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Roche Thrombogenic Agents Product Portfolio
  66. 4.11.5 Roche Recent Developments
  67. 4.12 Chongqing Laimei Pharmaceutical
  68. 4.12.1 Chongqing Laimei Pharmaceutical Company Information
  69. 4.12.2 Chongqing Laimei Pharmaceutical Business Overview
  70. 4.12.3 Chongqing Laimei Pharmaceutical Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Chongqing Laimei Pharmaceutical Thrombogenic Agents Product Portfolio
  72. 4.12.5 Chongqing Laimei Pharmaceutical Recent Developments
  73. 4.13 Jiangsu Yabang Aipson Pharmaceutical
  74. 4.13.1 Jiangsu Yabang Aipson Pharmaceutical Company Information
  75. 4.13.2 Jiangsu Yabang Aipson Pharmaceutical Business Overview
  76. 4.13.3 Jiangsu Yabang Aipson Pharmaceutical Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Jiangsu Yabang Aipson Pharmaceutical Thrombogenic Agents Product Portfolio
  78. 4.13.5 Jiangsu Yabang Aipson Pharmaceutical Recent Developments
  79. 4.14 Pfizer
  80. 4.14.1 Pfizer Company Information
  81. 4.14.2 Pfizer Business Overview
  82. 4.14.3 Pfizer Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Pfizer Thrombogenic Agents Product Portfolio
  84. 4.14.5 Pfizer Recent Developments
  85. 4.15 Boya Biopharmaceutical
  86. 4.15.1 Boya Biopharmaceutical Company Information
  87. 4.15.2 Boya Biopharmaceutical Business Overview
  88. 4.15.3 Boya Biopharmaceutical Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Boya Biopharmaceutical Thrombogenic Agents Product Portfolio
  90. 4.15.5 Boya Biopharmaceutical Recent Developments
  91. 4.16 Amgen
  92. 4.16.1 Amgen Company Information
  93. 4.16.2 Amgen Business Overview
  94. 4.16.3 Amgen Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Amgen Thrombogenic Agents Product Portfolio
  96. 4.16.5 Amgen Recent Developments
  97. 4.17 AbbVie
  98. 4.17.1 AbbVie Company Information
  99. 4.17.2 AbbVie Business Overview
  100. 4.17.3 AbbVie Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 AbbVie Thrombogenic Agents Product Portfolio
  102. 4.17.5 AbbVie Recent Developments
  103. 4.18 Johnson And Johnson
  104. 4.18.1 Johnson And Johnson Company Information
  105. 4.18.2 Johnson And Johnson Business Overview
  106. 4.18.3 Johnson And Johnson Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Johnson And Johnson Thrombogenic Agents Product Portfolio
  108. 4.18.5 Johnson And Johnson Recent Developments
  109. 4.19 BristolMyers Squibb
  110. 4.19.1 BristolMyers Squibb Company Information
  111. 4.19.2 BristolMyers Squibb Business Overview
  112. 4.19.3 BristolMyers Squibb Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 BristolMyers Squibb Thrombogenic Agents Product Portfolio
  114. 4.19.5 BristolMyers Squibb Recent Developments
  115. 4.20 Boehringer Ingelheim
  116. 4.20.1 Boehringer Ingelheim Company Information
  117. 4.20.2 Boehringer Ingelheim Business Overview
  118. 4.20.3 Boehringer Ingelheim Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Boehringer Ingelheim Thrombogenic Agents Product Portfolio
  120. 4.20.5 Boehringer Ingelheim Recent Developments
5 Global Thrombogenic Agents Market Scenario by Region
  1. 5.1 Global Thrombogenic Agents Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Thrombogenic Agents Sales by Region: 2021-2032
  3. 5.2.1 Global Thrombogenic Agents Sales by Region: 2021-2026
  4. 5.2.2 Global Thrombogenic Agents Sales by Region: 2027-2032
  5. 5.3 Global Thrombogenic Agents Revenue by Region: 2021-2032
  6. 5.3.1 Global Thrombogenic Agents Revenue by Region: 2021-2026
  7. 5.3.2 Global Thrombogenic Agents Revenue by Region: 2027-2032
  8. 5.4 North America Thrombogenic Agents Market Facts & Figures by Country
  9. 5.4.1 North America Thrombogenic Agents Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Thrombogenic Agents Sales by Country (2021-2032)
  11. 5.4.3 North America Thrombogenic Agents Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Thrombogenic Agents Market Facts & Figures by Country
  16. 5.5.1 Europe Thrombogenic Agents Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Thrombogenic Agents Sales by Country (2021-2032)
  18. 5.5.3 Europe Thrombogenic Agents Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Thrombogenic Agents Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Thrombogenic Agents Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Thrombogenic Agents Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Thrombogenic Agents Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Thrombogenic Agents Market Facts & Figures by Country
  41. 5.7.1 South America Thrombogenic Agents Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Thrombogenic Agents Sales by Country (2021-2032)
  43. 5.7.3 South America Thrombogenic Agents Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Thrombogenic Agents Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Thrombogenic Agents Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Thrombogenic Agents Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Thrombogenic Agents Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Thrombogenic Agents Sales by Type (2021-2032)
  2. 6.1.1 Global Thrombogenic Agents Sales by Type (2021-2032) & (units)
  3. 6.1.2 Global Thrombogenic Agents Sales Market Share by Type (2021-2032)
  4. 6.2 Global Thrombogenic Agents Revenue by Type (2021-2032)
  5. 6.2.1 Global Thrombogenic Agents Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Thrombogenic Agents Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Thrombogenic Agents Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Thrombogenic Agents Sales by Application (2021-2032)
  2. 7.1.1 Global Thrombogenic Agents Sales by Application (2021-2032) & (units)
  3. 7.1.2 Global Thrombogenic Agents Sales Market Share by Application (2021-2032)
  4. 7.2 Global Thrombogenic Agents Revenue by Application (2021-2032)
  5. 7.2.1 Global Thrombogenic Agents Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Thrombogenic Agents Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Thrombogenic Agents Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Thrombogenic Agents Value Chain Analysis
  2. 8.1.1 Thrombogenic Agents Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Thrombogenic Agents Production Mode & Process
  5. 8.2 Thrombogenic Agents Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Thrombogenic Agents Distributors
  8. 8.2.3 Thrombogenic Agents Customers
9 Global Thrombogenic Agents Analyzing Market Dynamics
  1. 9.1 Thrombogenic Agents Industry Trends
  2. 9.2 Thrombogenic Agents Industry Drivers
  3. 9.3 Thrombogenic Agents Industry Opportunities and Challenges
  4. 9.4 Thrombogenic Agents Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst